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The tumor suppressor p53 is activated by phosphorylation and/or acetylation. We constructed 14
non-phosphorylated, 11 phospho-mimetic, and 1 non-acetylated point p53 mutations and com-
pared their transactivation ability in U-87 human glioblastoma cells by the luciferase reporter assay.
Despite mutations at the phosphorylation sites, only the p53-K120R and p53-S9E mutants had mar-
ginally reduced activities. On the other hand, the Nuclear factor of activated T-cells (NFAT)-lucifer-
ase reporter was more potently activated by p53-K120R than by wild-type p53 and other mutants in
glioblastoma, hepatoma and esophageal carcinoma cells. This suggests that acetylation at Lys-120 of
p53 negatively regulates a signaling pathway leading to NFAT activation.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The tumor suppressor protein p53 possesses various biological
activities such as cell cycle arrest, induction of apoptosis and inhi-
bition of angiogenesis by transactivating p21 [1], Bax [2], PUMA
[3], Noxa [4], Bad [5], etc. The transactivation ability and the selec-
tivity of the target genes of p53 are assumed to be regulated
mainly by post-translational modiﬁcations including phosphoryla-
tion, acetylation, ubiquitination, methylation, neddylation and
sumoylation [6]. Despite numerous reports on p53, the precise
mechanism of selection of the target genes of activated p53 re-
mains to be proven.
Nuclear factor of activated T-cells (NFAT) was ﬁrst identiﬁed as
a transcription factor in activated, but not in resting, T cells [7,8].
NFAT is dephosphorylated by calcineurin and translocated into
the nucleus [9,10]. p53 also induces proline dehydrogenase 1
(PRODH1, proline oxidase, PIG6) [11,12] and proline dehydroge-
nase 2 (PRODH2, hydroxyproline oxidase) [13], both of which then
activate NFAT pathway through reactive oxygen and Ca2+/calcineu-
rin [14]. Although the NFAT pathway was suggested to be involved
in induction of apoptosis [15], NFAT has an oncogenic role in pan-
creatic carcinoma through transcriptional activation of c-myc [16].
In the present study, we show that a non-acetylated mutant,
p53-K120R, markedly activated NFAT.chemical Societies. Published by E
(T. Hiwasa).2. Materials and methods
2.1. Plasmids
pCMV-p53WT, pCMV-p53V143A [17], reporter plasmids and
pBV-PUMA-Luc [3] were provided by Dr. Bert Vogelstein (Howard
Hughes Medical Institute). pGL3-Bax-Luc, pGL3-p21-Luc and
pGL3-Bad-Luc [5] were provided by Dr. Mian Wu (University of
Science and Technology of China). pGV-B2 Noxa-Luc [4] was
provided by Dr. Nobuyuki Tanaka (Nippon Medical School).
NFAT-Luc and SV40-Rluc were purchased from Promega
(Madison, WI).
2.2. Cell culture
Human glioblastoma U-87, hepatocarcinoma HepG2, esopha-
geal carcinoma YES-4 and bladder carcinoma T-24 cells were cul-
tured in Dulbecco’s modiﬁed Eagle’s minimum essential medium
supplemented with 10% fetal bovine serum.2.3. Construction of p53 point mutants
p53 mutants were constructed from pCMV-p53 using KOD-
Plus-Mutagenesis kit (Toyobo, Osaka, Japan). The primers used
are listed in Table 1 (Supplementary data). All constructs were con-
ﬁrmed by base sequencing.lsevier B.V. All rights reserved.
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Fig. 2. Activation of p53 reporter plasmids by p53 mutants. U-87 glioblastoma cells (5  104 cells) were co-transfected with p53-responsive reporter plasmids (p21-Luc, Bax-
Luc, PUMA-Luc, Noxa-Luc, Bad-Luc or NFAT-Luc; 100 ng), transfection standard SV40-Rluc (10 ng), and the expression plasmid (0.5 lg) of p53-WT or p53 mutants, or control
empty vector pCMV-Neo-Bam. Cells were harvested 48 h after transfection and luciferase activities in the cell extracts were measured. The error bars represent S.D. (n = 3).
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Fig. 1. Expression of p53 in p53-transfected cells. U-87 human glioblastoma cells were transfected with expression plasmids of pCMV-Neo-Bam (Vector), p53-WT or p53
mutants. Expression levels of p53 proteins in the cytoplasmic (A) and nuclear fractions (C) were examined by Western blotting analysis using anti-p53 (DO-1) with loading
controls, anti-a/b-tubulin for the cytoplasmic fractions (B) and anti-Cdc2 antibodies for the nuclear fractions (D).
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Fig. 2. (continued)
1918 N. Shinmen et al. / FEBS Letters 583 (2009) 1916–19222.4. Western blotting analysis
U87 cells (1  106 cells) were transfected with p53 expression
plasmids (10 lg) using LipofectAMINE-Plus (Invitrogen, Carlsbad,
CA) and cultured for 2 days. As indicated, cells were treated with
nutlin-3 (10 lM) or the solvent dimethylsulfoxide (0.1%) for 24 h
before harvest. Cell extracts were prepared by treatment with
0.5% Nonidet P-40, 20 mM Tris–HCl (pH 7.5), 1 mM EDTA, 1 mM
phenylmethylsulfonyl ﬂuoride, 50 lM leupeptin, 50 lM antipain,
50 lM pepstatin A and 50 lM ALLN [18] for 10 min at 4 C [19].
The cell lysate was fractionated into the cytoplasmic (supernatant)
and the nuclear (pellet) fractions by centrifugation at 13000g for
10 min as described previously [19,20]. Proteins were separated by
SDS–polyacrylamide gel electrophoresis and blotted onto nitrocel-
lulose membranes. The ﬁlters were blocked using 0.5% non-fat dry
milk and were subsequently probed with primary antibodies suchas anti-p53 (DO-1, Santa Cruz Biotechnology, Santa Cruz, CA), anti-
a/b-tubulin (Cell Signaling, Danvers, MA) and anti-Cdc2 (Santa
Cruz Biotechnology). The membranes were then incubated with
horseradish peroxidase-conjugated secondary antibodies such as
donkey anti-mouse IgG and goat anti-rabbit IgG (Santa Cruz Bio-
technology) followed by treatment with Immobilon Western
Chemiluminescent Substrate (Millipore Corporation, Billerica, MA).
2.5. Luciferase assay
The cells seeded on 24-well plates were transfected with p53
expression plasmids together with ﬁreﬂy luciferase and control
Renilla luciferase reporter plasmid, SV40-Rluc, by using Lipofect-
AMINE-Plus (Invitrogen). Two days after the transfection, ﬁreﬂy
and Renilla luciferase activities were determined with a Dual Lucif-
erase Assay System (Promega) and a luminescencer (Atto, Tokyo,
N. Shinmen et al. / FEBS Letters 583 (2009) 1916–1922 1919Japan) as reported previously [19]. Fireﬂy luciferase activities were
normalized with the Renilla luciferase control activities.
2.6. Reverse transcription-PCR (RT-PCR)
Total cellular RNA was isolated from cultured cells using the
AquaPure RNA Isolation kit (Bio-Rad, Hercules, CA). Reverse tran-
scription was performed with an oligo(dT)20 primer using the Ther-
moScript RT-PCR System (Invitrogen). PCR primers and conditions
are shown in Tables 2 and 3, respectively (Supplementary data).
3. Results
3.1. Construction of p53 point mutants and transfection
We ﬁrst examined the expression levels of p53 proteins in U-87
glioblastoma cells transfected with p53 expression plasmids.
Nearly equal amounts of p53 protein were observed (Fig. 1).
Wild-type p53 (p53-WT) and most of the mutant proteins were ex-
pressed predominantly in a 53-kDa form. On the other hand, p53-
S9E showed multiple shift bands, of which the apparent molecular
weights suggested the ubiquitinated forms of p53.
Relative cytoplasmic and nuclear distribution was not largely
different among the p53 mutants. However, nuclear localization
of p53-S15A, p53-S378E and p53-S392E was limited.
3.2. Comparison of reporter activation by p53 mutants
We then examined the transcription activity of p53 mutants by
luciferase reporter assay using the promoter sequences of p53 tar-
get genes such as p21, Bax, PUMA, Noxa and Bad. p21-Luc was acti-
vated by p53-WT 21-fold, and similarly by most of the p53
mutants (Fig. 2A). p53-S9E showed the least activation (8-fold).
Similar results were obtained with Bax-Luc. p53-WT activated
Bax-Luc 60-fold, and p53-S9E, p53-S46E and p53-S55E showed rel-
atively weak activation (Fig. 2B). p53-WT activated PUMA-Luc 4.5-
fold, and p53-S9E and p53-S15A showed less activity (Fig. 2C).
p53-WT activated Noxa-Luc 11-fold, and p53-S15A and p52-S46A
showed less activation (Fig. 2D). p53-K120R activated Noxa-Luc0
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Fig. 3. Dose-dependent activation of NFAT-Luc and Noxa-Luc by p53-WT and p53-K120
reporter plasmid NFAT-Luc (100 ng), transfection standard SV40-Rluc (10 ng), and the ind
vector was used to adjust the total amount of plasmid DNA. Cells were harvested 48 h aft
bars represent S.D. (n = 3).more potently than p53-WT. Bad-Luc was activated by p53-WT
5-fold, and p53-S33E showed approximately 2-fold activation as
compared to that by p53-WT and other p53 mutants (Fig. 2E).
We also examined a number of other reporter plasmids. Among
them, NFAT-Luc was activated approximately 5-fold by p53-WT
and most of the p53 mutants whereas p53-K120R activated
NFAT-Luc 27-fold (Fig. 2F).
3.3. Dose-dependent activation of NFAT-Luc byp53-K120R mutant
We analyzed further the dose-responsive activation of NFAT-
Luc and Noxa-Luc by p53-WT and p53-K120R. p53-K120R acti-
vated NFAT-Luc much more effectively than p53-WT at any dose
(Fig. 3).
3.4. Activation of NFAT-Luc byp53-K120R mutant in hepatoma,
esophageal carcinoma and bladder carcinoma cells
p21-Luc and Bax-Luc were activated by p53-WT more potently
than by p53-K120R in HepG2, YES-4 and T-24 cells (Fig. 4a, b, e, f, i
and j). PUMA-Luc was activated by p53-WT in T-24 cells but not in
HepG2 and YES-4 cells (Fig. 4c, g and k). p53-K120R showed lower
activity than p53-WT toward PUMA-Luc in T-24 cells. Much more
potent activity of p53-K120R than p53-WT was also observed to-
ward NFAT-Luc in HepG2 and YES-4 cells, yet it was less prominent
in T-24 cells (Fig. 4d, h and l).
3.5. PRODH induction was not potentiated in p53-K120R
We then examined the mRNA levels of p53 targets. U-87 cells
were transfected with an empty vector, p53-WT or p53-K120R,
and then treated with or without nutlin-3 which increased p53
protein by inhibiting MDM2 [21]. The mRNA levels of PRODH1 as
well as p21 and MDM2 increased after treatment with nutlin-3,
transfection with p53-WT cDNA or both (Fig. 4). Transfection with
p53-K120R showed less activity than p53-WT against PRODH1 and
almost no effect on p21 and MDM2 mRNA expression. The mRNA
level of PRODH2 was not apparently altered by nutlin-3 treatment
or p53 transfection.C
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NFAT-Luc was examined using HepG2 hepatocarcinoma, YES-4 esophageal carcinoma and T-24 bladder carcinoma cells as indicated. The error bars represent S.D. (n = 3).
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In the present study, we constructed 26 point mutants of p53
and examined their transactivation ability by luciferase reporter
assay. It has been well documented that phosphorylation at amino
acids in the transactivation domain of p53 may reduce the binding
afﬁnity to MDM2 and increase the p53 protein expression levels by
suppressing the MDM2-mediated ubiquitination and subsequent
degradation [22,23]. Relative protein expression levels of the p53mutants were similar to p53-WT (Fig. 1a and c). Thus, inhibition
of phosphorylation at a sole amino acid position was not sufﬁcient
to affect the protein expression levels. Consistently, even a p53
mutant with combined mutation of serines 6, 9, 15, 20, 33 and
37 (N6A) caused a marginal effect in induction of the target genes
[24]. A phospho-mimetic mutant, p53-S9E, showed a ubiquitina-
tion-like mobility shift through SDS gel electrophoresis (Fig. 1a),
suggesting that the phosphorylation at Ser-9 facilitates ubiquitina-
tion of p53. Nuclear localization of p53-S15A and p53-S46A was
-actin
MDM2
p53
p21
PRODH1
Nutlin-3   -      +        -      +       -       +
ve
cto
r
p5
3-W
T
p5
3-K
12
0R
PRODH2
Fig. 5. Comparison of target gene induction between p53-WT and p53-K120R. U-87
cells were transfected with an empty vector or the expression plasmid of p53-WT or
p53-K120R, cultured for 24 h, and then treated with or without nutlin-3 at 10 lM
for 24 h. mRNA expression levels of PROD1, PROD2, p21, MDM2, p53 and b-actin
(loading control) were examined by RT-PCR.
N. Shinmen et al. / FEBS Letters 583 (2009) 1916–1922 1921partly suppressed (Fig. 1c), probably relating to MDM2-mediated
nucleo-cytoplasmic shuttling [25].
Acetylation of p53 is indispensable for p53 biological activities
[26]. Among multiple acetylation sites of p53 (positions 120, 164,
370, 372, 373, 381, 382 and 386), acetylation at Lys-120 plays a
key role in induction of apoptosis [27]. However, thus far, no dis-
tinct biochemical activity is known for the point mutation at this
site. We found that the NFAT signaling pathway was activated
much more potently by the p53-K120R mutant than by p53-WT
and other mutants (Figs. 2F and 3). This prominent characteristic
was not due to the different protein expression levels as conﬁrmed
by Western blotting (Fig. 1). On the other hand, p53-K120R acti-
vated p21-Luc less potently than p53-WT (Fig. 2A), which is com-
patible with the report that a comparable mutant, p53-K120A, was
deﬁcient for transactivation of p21 [28].
PRODH1 was ﬁrst identiﬁed as PIG6 which was induced by p53
[11], and recently, PRODH2 was also shown to be transactivated by
p53 [13]. An increase in the expression levels of either or both of
PRODH1 and PRODH2 results in production of reactive oxygens fol-
lowed by an increase in calcium mobilization, activation of calci-
neurin and then an increase of NFAT transactivity by nuclear
translocation [14]. Thus, activation of NFAT-Luc by p53 may be
mediated by PRODH1 and/or PRODH2. Although p53-K120R in-
creased the mRNA level of PRODH1 to some extent, the level was
much less than the levels increased by p53-WT irrespective of
the treatment with nutlin-3 (Fig. 5). p53-K120R showed almost
no effect on the levels of p21 and MDM2. These different mRNA
induction abilities between p53-WT and p53-K120R is consistent
with the results of a reporter assay using p21-Luc and Bax-Luc
(Fig. 2). The mRNA level of PRODH2 was not apparently altered
by nutlin-3 treatment and/or p53 transfection. Thus, the remark-
able activation of NFAT-Luc by p53-K120R cannot be attributed
to the induction of PRODH1 and PRODH2.
Prominent activation of NFAT-Luc by p53-K120R as compared
to p53-WT was observed in U-87 glioblastoma (Figs. 2 and 3),
HepG2 hepatocarcinoma and YES-4 esophageal carcinoma cells
(Fig. 4). On the other hand, p53-K120R and p53-WT showed similar
activity against NFAT-Luc in T-24 bladder carcinoma cells. Activa-
tion of PUMA-Luc by p53-WT was observed in U-87 and T-24 cells
but not in HepG2 and YES-4 cells (Figs. 2 and 4). These cell-type-
dependent effects imply that the selection of the target genes
and following signal pathways of p53 is affected by transcriptionco-factors such as TBP [29], TAFII 31 [30], CBP [31], PC4 [32] and
LKB1 [33].
NFAT is frequently overexpressed in tumor tissues and may
possess an oncogenic role [16]. The present study shows that a
Lys-120-deacetylated form of p53 facilitates activation of NFAT.
In other words, acetylation at Lys-120 may reduce the induction
of NFAT-responsive target genes by increasing other p53-respon-
sive growth-inhibitory and/or proapoptotic genes, which results
in more effective tumor suppression. This may account for the
importance of Lys-120 in p53’s biological activity.
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